Focus: Armata Pharmaceuticals is a public biotech company developing natural and synthetic bacteriophage-based therapies, primarily targeting infectious diseases and dental applications. The company is in early-stage clinical development with no approved products or commercial revenue.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Armata Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Armata Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Armata Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP Moomoo
Director Daniel Gilmer reported as insider at Armata Pharmaceuticals (ARMP) - Stock Titan
Director Daniel Gilmer reported as insider at Armata Pharmaceuticals (ARMP) Stock Titan
8-K Filing: Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) — EX-99.1
EX-99.1
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - Morningstar
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update Morningstar
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags Seeking Alpha
8-K Filing: Innoviva, Inc. (INVA) (CIK 0001080014) — EX-99.1
EX-99.1
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo